Antithrombotic activity of a protease purified from a medicinal mushroom, Ganoderma lucidum, has been evaluated platelet aggregation in vitro and pulmonary thrombosis in vivo. The purified protease exhibited concentration dependent inhibitory effects on platelet aggregation induced by ADP （adenosine diphosphate） , with an IC50 value of 2.4 mg/mL. The purified protease protected mice against thrombotic death or paralysis induced by collagen and epinephrine in a dose dependent manner when administered orally. It produced a significant inhibition of thrombotic death or paralysis at 60 μg/kg body weight, while aspirin produced a significant inhibition of thrombosis at 10-20 mg/kg body weight. The purified protease also has showed fibrinolytic activity and alters coagulation parameters such as activated partial thromboplastin time（APTT） , and thrombin time（TT）in rat platelet. These results suggested that the antithrombotic activity of Ganoderma lucidum protease might be due to antiplatelet activity rather than anticoagulation activity.
Introduction
Thromboembolic diseases are the leading cause of mortality and morbidity worldwide 1） . Despite the well-established application of antithrombotic drugs, such as anticoagulants, antiplatelet drugs, and thrombolytic drugs, there is still an urgent need for more potent and safer compounds for the prevention and treatment of ischemic symptoms 2−4） . Intravascular thrombosis, caused by a blood clot formed in a blood vessel, is a main cause of cardiovascular diseases（CVDs） . The World Health Organization（WHO）has reported that about 17 million people die of CVDs each year 5） , therefore, research is underway to develop cheaper and safer antithrombotic agents from various sources. During blood clot formation, fibrinogen is converted into fibrin via the proteolytic action of thrombin, this result in the formation of insoluble fibrin clots 6） . Therefore, fibrin, fibrinogen, and thrombin are important targets in the screening of antithrombotic agents. Ganoderma lucidum is a popular medicinal mushroom, which has been used in traditional Chinese medicine for the prevention or treatment of a variety of diseases; it is also considered a thermotolerant fungus 7） , which fungus utilizes sugars, phenols, catechol, and phloroglucinol. It also degrades lignin, its model compound inulin and flavonoids such rutin, quercetin and catechin 8） . In the East Mediterranean countries, Ganoderma species are regarded as an herb of longevity. These fungi have been used in folk medicine for hundreds of years and strains are commercially cultivated for use in the preparation of health tablets 9） . Medicinal benefits of Ganoderma spp have been reviewed by Jong and Brimogham 10） . Six novel triterpenoids, i. e ganoderenic acid, furano ganodermic acid and ganoderic acid derivatives, have been isolated from the fruit body of the fungus Ganoderma applanatum
11）
. Extracts or prescriptions of Ganoderma lucidum are have been known to play a role in many kinds of antiinflammation and anti-proliferative treatment 12） . It is an important non-toxic medicinal mushroom, and commonly available as a pathogen of many angiosperm trees. The isolates of G. lucidum can be easily cultured however there are no reports available regarding their harmfulness to humankind. Hence, these isolates are considered to be a suitable candidate for industrial exploitation and therefore a search was been carried out in the present study for the fibrinolytic protease from different isolates of this fungus collected exclusively from localities in Southern India and its antithrombotic effect was investigated.
Materials and methods

Sample collection
The basidiocarps of different strains of G. lucidum were collected from host trees belonging to gymnosperms and angiosperms in different climatic regions of Southern India. The cortex tissue of the basidiocarps was used for raising cultures on agar plates and identified by following the method of Leelavathy and Ganesh
14）
. The strains were maintained on potato dextrose agar （PDA）medium. Cultures were grown on Czapek's Dox agar（CDA）medium at room temperature for 5 days and from them 5 mm dia mycelial discs were obtained and used as the initial inocula for the experiments described below.
Screening of G. lucidum isolates for fibrinolytic protease
All the isolates of G. lucidum were screened for both caseinolytic and fibrinolytic activities by measuring the lytic zone in a medium which included skim milk powder as the substrate using the methods described by Astrup and Mullertz
15）
and Rajamani and Hilda
16）
.
Purification of fibrinolytic enzyme
The mycelium inoculum prepared using G. lucidum VK12 as described above was inoculated into Modified Czapek's Dox broth amended with fibrin（MCDBF）medium and incubated at 30℃ for 15 days under a shaking condition（150 rpm）in an orbital shaker（Lab-Line Instruments-Inc, India） .
The mycelia mat grown in the MCDBF medium was collected by filtering through several layers of cheesecloth, washed with 300 mL of Tris-HCl buffer（0.05 M, pH 7.4） and stored frozen at -20℃ until further use. Five hundred grams of frozen mycelia were thawed and homogenized with an equal volume（500 mL）of Tris-HCl buffer,（10 mM, pH 7.4）for 5 min at maximum speed. The homogenate was centrifuged at 10,000 × g for 30 min in a refrigerated centrifuge（Beckman Inc, USA） . The supernatant was subjected to protein precipitation with ammonium sulfate at 30, 60 and 80% saturation levels. The protein pellet obtained after centrifugation was dissolved in 10 mL of Tris HCl buffer（10 mM, pH 7.4）and dialyzed against the same buffer for 48 h at 4℃. The dialysate was concentrated by lyophilization and used for enzyme purification on a DEAE anion exchange column. The activated DEAE anion exchanger was packed in a glass column（2 × 3 cm）and thoroughly washed in distilled water and equilibrated with Tris-HCl buffer（20 mM; pH 7.4） . The proteins were adsorbed onto the column and eluted with Tris-HCl buffer（20 mM; pH 7.4）using a linear gradient of sodium chloride（0.1-1.0 M） in the buffer. Protein fractions（5 mL）were collected and were assayed for enzyme activity. The protease active fractions were pooled and concentrated by freeze-drying and purify further on a Sephadex G-150 column（2 × 100 cm） . Fractions were eluted with 20 mM Tris-HCl buffer（pH 7.2） at a flow rate of 3 mL/16 min. The protease active fractions were again pooled, concentrated and the purity was analyzed on SDS-PAGE after silver staining.
Analysis of fibrinolytic enzyme using Fibrin Zymography Fibrin zymography was performed in SDS-PAGE under a non-reducing condition as described by Kim et al.
17）
. Fibrinogen（0.12% w/v） and thrombin（1 unit/mL）were incorporated into the resolving gel solution just before acrylamide polymerization. The purified protease（10 μg） was separated on the gel. After separation the gel was washed twish with Tris-HCl buffer（20 mM; pH 7.2）with Triton X-100（1%）and incubated in the same buffer without Triton X-100 at 37℃ overnight. The gel was then stained with Coomassie brilliant blue R-250. The presence of a fibrinolytic protease activity band was observed after removing the excess stain from the gel with the destaining solution.
Fibrinogenolytic activity of purified protease
The fibrinogenolytic activity was measured as described by Datta et al., uha
18）
. The purified fibrinolytic protease（10 μg）was mixed with 80 μL of 1% fibrinogen prepared with 20 mM Tris-HCl, 7.2, containing 0.15 M NaCl and incubated at 37℃ for different periods of time i.e., 5, 20, 40, 60, 80, 100 and 120 min. A portion（20 μL）of the reaction mixture was analyzed on SDS-PAGE 19） to examine the cleavage pattern of the fibrinogen chains.
Antiplatelet activity
The antiplatelet activity was determined with male Balb/c mice（25-30 g）obtained from the Laboratory Animal Maintenance Unit, Tamilnadu Animal Sciences and Veterinary University, Chennai, INDIA. The animals were acclimatized to the ambient laboratory conditions 25 ± 2℃ with 12/12 hours of light-dark cycle and were given standard rat feed（Hindustan Lever Ltd., Bangaluru）and water ad libitum. Rats weighing 170-230 g were used for platelet preparation and blood from these rats was drawn into a syringe containing 1/6 volume of ACD-C （130 mM citric acid, 124 mM trisodium citrate, 110 mM glucose） . The platelet-rich-plasma（PRP） was obtained by centrifugation at 120 × g, 15 min at room temperature. The platelets were washed free of plasmatic contaminants 20） and resuspended in a buffer containing 11.9 mM NaHCO3, 0.33 mM NaH2PO4, 16.3 mM NaCl, 2.8 mM KCl, 1.1 mM MgCl2, 11.1 mM glucose, pH 7.4, in order to adjust the platelet counts in 3.5 × 10 6 /mL. Platelet aggregation was measured by the method of Born and Cross 21） using an aggregometer. About 470 μL of washed PRP suspension was placed in the cuvette of the aggregometer and incubated at 37℃ for 5 min. To this, 10 μL of CaCl2 solution（final concentration 1.0mM）and 10 μL of a test solution were added successively with a 2 min interval after each addition. Platelet aggregation was induced by the addition of 10 μL of ADP solution （final concentration 10 μM） . The extent of platelet aggregation was expressed as % inhibition（×） using the following equation: X= ［ （A − B） /A］ × 100, where A is the maximal aggregation rate of saline treated platelets, and B is the maximal aggregation rate of sample treated platelets. IC50 was determined as the antiplatelet activity.
In vitro anticoagulation assay Measurements of plasma activated partial thromboplastin time（APTT）and thrombin time （TT）were performed by modifying Hara's 22） method using an Automated Coagulation Laboratory 100 instrument and an ACL-assay reagent kit as previously described 23） . In brief, the platelet poor plasma（PPP）was incubated with various concentrations（10, 20, 30, 40 and 50 μg/mL）of purified protease and heparin（1 and 10 μg）for 7 min at 37℃. Then, 100 μL of the incubated plasma was mixed with 50 μL of cephalin in the process plate, and the coagulation was started by addition of CaCl2（1mM） , 100 μL of thromboplastin and 100 μL bovine thrombin into the 100 μL of incubated plasma for APTT and TT assay respectively. Anticoagulatory activity of purified protease was evaluated by comparing it with the plasma clotting time in untreated control.
Thromboembolism mouse model for purified protease
The antithrombotic effect of purified protease was performed using the mouse pulmonary thrombosis test by the method of Diminno and Silver
24）
. Purified protease（20, 40 and 60 μg/kg） and aspirin（20 mg/kg）were used as a positive control and orally administered to Balb/c mice after overnight fasting. Ninety minutes after oral administration, a mixture of solution containing collagen（114 μg/mouse）plus epinephrine（1.83 μg/mouse）was injected into the tail vein to induce pulmonary thrombosis 25） . Three animal studies were performed. A group of 12 mice was used in each of the three experiments. The number of dead or paralyzed mice was counted for 15 min, and the survival rate（%）was calculated by the following equation: Survival rate X= （1-（dead or paralyzed mice） /total mice tested） × 100.
Statistical analysis
The experimental results were expressed as the mean ± S. E. M. Analysis of variance was performed by using SPSS（SPSS Inc., USA） . Duncan's new multiple range test was used to determine the difference of means, and p ＜ 0.05 was considered statistically significant. The χ 2-test was used to determine whether there were significant differences in between mice that received an antithrombotic agent and the controls which did not.
Results
Screening of G. lucidum isolates for fibrinolytic protease
All the isolates of G. lucidum hydrolyzed the substrate incorporated in the medium. An isolate designated as VK12 collected from Tamarindus indica showed relatively higher fibrinolytic activity followed by VK06 and VK07 isolated from Enterolobium saman and innamomum camphora, respectively（Table 1） . The growth of isolate VK12 on agar plate was comparatively higher than the growths of the other two fibrinolytic positive isolates. Therefore, this isolate was chosen for the production and purification of fibrinolytic protease in this study.
Purification of fibrinolytic enzyme
The intracellular fibrinolytic protease enzyme isolated from the mycelia mat was purified by a combination of techniques: ammonium sulfate fractionation, ion exchange chromatography and Sephadex G-150 column chromatography, and the recovery and purification fold are listed in at 80% saturation showed relatively higher protease activity than those obtained after 30 and 60% saturation. Therefore, only the proteins obtained with 80% saturation were used for further purification on a DEAE-cellulose anion exchange column. The proteins were eluted with Tris-HCl buffer（10 mM; pH 7.2）with linear gradient of NaCl（0.1-1.0 M） . Of the 50 fractions collected, relatively higher protease activity was recorded in fractions 15-28 eluted with a 0.5 to 0.7 NaCl. These fractions were pooled together, concentrated and used for further purification on Sephadex G-150 column chromatography. A total of 100 fractions were collected and a major peak of activity was resolved in fractions 22-40. These fractions were pooled, concentrated and dialyzed against Tris-HCl buffer（10 mM; pH 7.2） . Twelve mg of the purified enzyme was obtained at 14.4-fold from 500 g of G. lucidum mycelium with a yield of 44.6%（Table 2） . The purity of the enzyme was checked on SDS-PAGE after silver nitrate staining and the purified enzyme appeared as a single homogenous band（Fig. 1; lane 4） . The molecular mass of the fibrinolytic enzyme was determined to be 33.2 kDa. The purified protease of G. lucidum hydrolyzed the substrate fibrin which was incorporated in the gel. The hydrolytic activity appeared as a clear and single homogenous band（Fig. 1, Lane 5）against a blue background.
N-terminal sequencing of fibrinolytic protease of G. lucidum
A 20 amino acid sequence of the N-terminal region of the purified fibrinolytic protease was obtained by the Edman degradation method and the sequence obtained was, QQRFPQRYVQ-LVITVDHVMN. The sequence was deposited in SWISS PROT under the accession number P86051 .
The purified protease hydrolyzed A α and B β subunits of human fibrinogen but did not hydrolyze the γ chain; the enzyme preferentially degraded the A α-chain of fibrinogen within 5 min of incubation and degradation of the β-chain occurred at between 80-120 minutes（Fig.3） .
The activity of the purified protease of G. lucidum VK12 was completely inhibited by ADP （20 μM） , epinephrine（20 μM） , calcium ionophore A23187（10 μM）and collagen（50 μg/mL）and induced human platelet aggregation in a dose-dependent manner. The IC50 values of G. lucidum protease in human platelet aggregation induced Lanes: M. Protein molecular weight standards 1. Ammonium sulphate precipitated protein fraction-3 2. DEAE-cellulose column eluted proteins 3. Sephadex G-150 column eluted protein 5. Fibrin zymography（Protein molecular weight standards: 97 kDa-phosphorylase; 66 kDa-bovine serum albumin; 45kDa-ovalbumin; 30 kDa-carbonic anhydrase; 20.1 kDa-soybean inhibitor and 14.4kDa-α-lactalbumin） by ADP, epinephrine, calcium ionophore A23187 and collagen were 0.75, 0.42, 0.35, and 0.58 mg/mL respectively, while aspirin did not inhibit ADP-induced platelet aggregation at 2 mM（Table 3） .
Intravenous injection of a mixture of collagen and epinephrine into the tail vein of mice caused pulmonary thrombosis, resulting in death and of a survival rate of 8.3% in the control group. Oral administration of purified G. lucidum VK12 protease prior to the injection exhibited dose dependent preventive effects against thrombotic death or paralysis, providing a survival rate of 80.5, 72.5 and 36.2% at 60, 40 and 20 μm/kg, respectively （Table 4） , while the aspirin, a reference drug, showed a protective effect of 55.5% at 20 mg/kg.
The anticoagulant activity of purified G. lucidum VK12 fibrinolytic protease was investigated using the classical coagulation assay APTT and TT with heparin（140 USP units/mg）as a reference drug. APTT is related to the intrinsic coagulation phase in plasma, whereas TT is related to the third coagulation phase in plasma. Anticoagulant activity of G. lucidum VK12 protease and heparin was measured by APTT and TT. The purified protease prolonged the APTT and TT in a concentration-dependent manner. G. lucidum VK12 protease prolonged APTT and TT beyond 37 and 28s at plasma concentrations greater than 6 μg/mL, 2.4-fold more G. lucidum VK12 protease required than heparin to prolong APTT and TT to 37 and 38s. At 2, 4 and 6 μg/ml of plasma, the anticoagulant activity was 20 μg（34s） , 30 μg（30s）and 40 μg（37s） , which is double that of the control （12.9） . The anticoagulant effect of the G. lucidum protease was alsoevaluated by the TT test. The anticoagulant activity was about 20 μg（36s） , 30 μg（37s）and 40 μg（38s）which was 2 times greater than that of the control heparin（16s）at the same concentrations. The prolongation of APTT suggested inhibition of the intrinsic coagulation pathway whereas prolongation of TT indicated inhibition of thrombin-mediated fibrin Lanes: M-Protein molecular weight standards F-Fibrinogen Lanes 1-7 intact fibrinogen incubated with purified fibrinogenolytic activity for the time period mentioned below 1-After 5 mins 2-After 20 mins 3-After 40 mins 4-After 60 mins 5-After 80 mins 6-After 100 mins 7-After 120 mins formation. As a reference drug, heparin significantly prolonged TT to 16.33s at 1 μM and completely blocked the coagulation at 10 μM （Table 5） .
Discussion
An attempt has been made in the present study to isolate different strains of G. lucidum from different ecological niches in Southern India. As many as 24 isolates were isolated and the pure cultures were maintained on PDA. Growth studies were performed on agar plates and a strain designated VK 12 isolated from Tamarindus indica showed relatively higher growth than other strains（Table 1） . All the strains were screened for the production of fibrinolytic protease using the fibrin agar plate assay. The fibrin agar plate assay was performed as follows. Fibrin, the substrate for the fibrinolytic protease enzymes, was obtained by the proteolytic conversion of fibrinogen by the enzyme thrombin. The strains of G. lucidum were grown on fibrin incorporated medium and the extent of hydrolytic activity was measured in terms of the lytic zone. All the strains hydrolyzed the substrate incorporated in the medium, however strain VK 12 exhibited relatively higher protease activity than other strains（Table 1） . Therefore, this particular strain was chosen for the isolation and purification of fibrinolytic protease from the mycelial mats. Different purification techniques such as ammonium sulfate fractionation, DEAE-Cellulose anion exchange chromatography and Sephadex G-150 column chromatography were used to purify the intracellular protease. The first level of protein purification was performed with ammonium sulfate fractionation method. The protein precipitated with 80% ammonium sulfate saturation showed higher protease activity than proteins obtained after 30 and 60% saturation. Therefore, the protein precipitated after 80% saturation were used for further purification. The second level of purification was carried out with anion exchange chromatography. Fractions eluted from the column were assayed for protease activity as described in Materials and Methods and fractions 15-28 eluted with a 0.5 to 0.7 NaCl showed a single peak of activity. These fractions were pooled concentrated and used for further purification on Sephadex G-150 column chromatography. All the fractions eluted from this column were tested for protease activity and there was again a single peak of activity collected in the fractions 22-40. These fractions were combined and concentrated by lyophilization. The purity of the enzyme was analyzed on SDS-PAGE after silver staining. As shown in Fig. 1（lane 4）the enzyme appeared as a single nearly homogeneous band. The purified enzyme was also analyzed for its activity on SDS-PAGE incorporated with the substrate fibrin which was obtained as described below. Fibrinogen and thrombin were added to the resolving gel solution just before polymerization. The proteolytic cleavage of fibrinogen by thrombin resulted in the formation of fibrin during the acrylamide polymerization. The fibrin so formed served as the substrate for fibrinolytic enzymes. As is evident in Fig.1（lane 5）the purified enzyme hydrolyzed the substrate and the hydrolyzed region appeared as a transparent band while the remaining area of the gel appeared blue. The appearance of hydrolytic band in the gel not only reveals the fibrinolytic activity of the purified enzyme but also indicates the successful formation of fibrin in the gel. The molecular mass of the lucidum has a molecular mass of 52 kDa. It is not clear if the 33.2 kDa fibrinolytic protease obtained in the present study could be a mutated one of the 52 kDa protease observed by these researchers. In the absence sequence data it is difficult to say it is a mutated one. The phylogenetic tree was constructed using the N-terminal amino acid sequence of the purified protease and its relative sequences obtained from the NCBI GenBank by the minimum evolution method. Sequences were grouped within the phylogenetic divisions depending on the robustness of bootstrap values from the phylogenetic analysis in which values above 60% were considered to be good bootstrap values. The purified protease of G. lucidum has therefore been phylogenetically affiliated with proteases of Agkistrodon contortrix contortrix （P28891） and Agkistrodon contortrix FFZM （AAB26922） , respectively（Fig. 2） .
The fibrinogenolytic activity of the purified enzyme was analyzed on SDS-PAGE after treating the fibrinogen with the enzyme for different periods of time. The enzyme preferentially degraded the A α and Bβ chains, however, the γ -chain remained intact throughout the incubation period（Fig. 3） . Fibrinolytic proteases characterized from G. , and this characteristic is quite different from the fibrinolytic protease purified from G. lucidum.
To investigate the interactions of G. lucidum VK12 protease with coagulation factors, the effects of the protease on coagulation time were evaluated by APTT and TT assays using PPP. None of the coagulation parameters tested was affected by the enzyme treatment at a concentration up to 10 μg/mL（Table 4） . These tests are often referred to as functional tests because they monitor clot formation 32） . Uncontrolled platelet aggregation is critical in arterial thrombosis which may cause life-threatening disorders such as heart attacks, unstable angina and reocclusion after angioplasty 33） . Hence, in the treatment and prevention of these cardiovascular diseases, the inhibition of platelet aggregation is of fundamental importance 34） . Although it is well established that aspirin still provides an effective secondary prevention of ischemic cardiovascular disorders, this drug can produce hemorrhagic events and upper gastrointestinal bleeding as major drawbacks. In the search for novel compounds or sources these considerations have led to an effort to suppress the platelet aggregation. G. lucidum has been used as a traditional food and medicine and its constituents extensively identified, but the biological potency of the fungus has not yet been sufficiently investigated. Our results suggest that G. lucidum protease could be a potent source of antithrombotic activity due to its antiplatelet activity. Most of the traditional uses of the fungus as a medicine have been to treat many kinds of inflammation, bleeding and poisoning. The antithrombotic effect of G. lucidum in this experiment may be contrary to the traditional use（to treat bleeding） . Further studies on the exact mechanism of action and components of G. lucidum VK12 protease are being made. Purified protease of G. lucidum VK12 showed a significant antithrombotic activity in vitro and in vivo, and this could be due to antiplatelet activity rather than to anticoagulation activity.
